EX-16.1 2 tm2422446d1_ex16-1.htm EXHIBIT 16.1

 

Exhibit 16.1

 

 

RSM US LLP

 

80 City Square

Boston, MA 02129

 

T +1 617 912 9000

F +1 617 912 9001

 

www.rsmus.com

 

August 22, 2024

 

Securities and Exchange Commission

Washington, D.C. 20549

 

Commissioners:

 

We have read Cyclacel Pharmaceuticals, Inc.’s statements included under Item 4.01(a) of its Form 8-K filed on August 22, 2024 and we agree with such statements concerning our firm.

 

/s/ RSM US LLP